Indefinite Delivery Contract SPE2DU25D9395

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was awarded a single-award Indefinite Delivery Contract (IDC) by the Defense Logistics Agency on November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The contract carries a ceiling value of $5.0 million with an ultimate completion date of December 31, 2036, structured as a 30-month base period followed by three optional 30-month renewal periods. As a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group is authorized to provide comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide. The product portfolio encompasses branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables, including oncology treatments (Keytruda, Tecentriq, Xtandi), immunosuppressants and biologic agents (Nucala, Xolair, Stelara, HEMLIBRA), emergency medications, specialty surgical products, contraceptive devices, and routine pharmaceuticals across antibiotic, antiviral, pain management, and other therapeutic categories.

The contract was established through the Defense Logistics Agency Troop Support Medical Supply Chain's competitive procurement requiring responsive and responsible offerors to provide the lowest overall pricing based on distribution fees applicable to both branded/generic and specialty pharmaceuticals. No set-asides were utilized in this unrestricted procurement. Delivery orders issued under this IDC are firm fixed-price arrangements designed to support recurring medical supply needs of military healthcare facilities globally, with documented delivery order activity demonstrating DMS Pharmaceutical Group's capability to manage diverse pharmaceutical requirements ranging from small purchases under $100 to significant orders exceeding $115,000. The contract positions the company as a critical supplier within the federal pharmaceutical supply chain, enabling the Defense Logistics Agency to fulfill specialized and routine pharmaceutical requirements for Department of Defense healthcare operations across multiple geographic regions and therapeutic categories through a streamlined indefinite delivery mechanism.